Overview

A Long-term Follow-up Study of Patients With MPS IIIA Treated With ABO-102

Status:
Enrolling by invitation
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
The main objective of this study is to evaluate the long-term safety and tolerability of ABO-102 in participants with MPS IIIA.
Phase:
Phase 3
Details
Lead Sponsor:
Ultragenyx Pharmaceutical Inc
Collaborator:
Abeona Therapeutics, Inc